Canatu receives further reactor order from FST, validating its CNT technology for pellicle manufacturing
Vantaa, Finland, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Canatu Plc (CANATU, Nasdaq First North Growth Market Finland) has received an order for further CNT100 SEMI reactor from Korean semiconductor company FINE SEMITECH CORPORATION (FST).
The order follows the previously announced purchase order for long-lead time items and represents the next step in the companies’ collaboration to scale the production of carbon nanotube (CNT) pellicle membranes for the semiconductor industry.
The total value of the reactor order, including the previously announced long-lead-time items order, is classified as “large” under Canatu’s disclosure policy, corresponding to a contract value of more than EUR 5 million and excluding royalties and other recurring elements. The reactor is expected to be delivered in 2027. Accordingly, while the order is expected to contribute to Canatu’s revenue already during the second half of 2026, the majority of the revenue generated from the order is expected to be recognized only in 2027.
Dr. Maximilian Slawinski, CEO of Canatu, commented:
“This reactor order demonstrates continued confidence in our unique CNT technology and reactor platform, while providing further validation of the growing market opportunity for CNT pellicles in advanced semiconductor manufacturing. It also marks another huge step towards the implementation of Canatu’s CNT Technology as a new standard for pellicles used in EUV semiconductor manufacturing. I am also very thankful for the expanding partnership with FST solidified by this milestone of the joint collaboration.”
Commercial adoption of CNT pellicle manufacturing continues
This order builds on a series of milestones in the commercialization of CNT membrane technology for pellicle manufacturing. Canatu shipped its first CNT100 SEMI reactor in September 2024. In July 2025, the reactor and associated post-processing equipment received customer approval, enabling commercial-scale manufacturing of advanced CNT-based EUV pellicles. In October 2025, Canatu granted FST a commercial production license, establishing the framework for royalty-bearing production.
Earlier in 2026, FST placed an order for long-lead time items. This reactor order represents the continuation of this commercialization pathway, expanding the customer’s manufacturing capacity of CNT pellicles.
Once commercial production using the additional reactor commences, Canatu expects to generate recurring revenues through royalties and proprietary consumables used in the CNT manufacturing process.
Additional information
Dr. Maximilian Slawinski, CEO, maximilian.slawinski@canatu.com
Mikko Vesterinen, CFO, mikko.vesterinen@canatu.com
Certified adviser
DNB Carnegie Investment Bank AB (publ), tel. +46 (0) 8 588 685 70
About Canatu
Canatu (CANATU, Nasdaq First North, Finland) is a deep technology scaleup company creating advanced carbon nanotubes (Canatu CNTs), related products, and manufacturing equipment for the semiconductor, robotics, mobility and defense, and medical diagnostics industries. Canatu partners with forerunner companies, together transforming products for better tomorrows with nano carbon.
Canatu’s versatile platform technology has broad potential applications. Its current core includes CNT membranes for extreme ultraviolet (EUV) processes in the semiconductor industry, enabling more effective manufacturing of the most advanced chips. Additionally, electrochemical sensors for medical diagnostics are in the development phase. Canatu’s patented CNT reactors and Dry Deposition by CanatuTM method yield clean and pristine CNTs. The company operates through two business models: selling CNT products directly, as well as selling CNT reactors and licensing the related technology so that customers can produce CNT products under a limited license.
Headquartered in Finland, Canatu also operates in the US, Japan and Taiwan. Founded in 2004 as a spin-off from Aalto University’s Nanomaterials Group, Canatu has 185 full-time equivalent employees representing over 35 nationalities, with nearly 20% holding or pursuing doctorates. Discover more at www.canatu.com and follow us on LinkedIn.
Attachment
